Restarting Wegovy After Two Months Off for Side Effects

What stopping for two months actually changes, and what it doesn't

Two months off semaglutide is long enough that most of the drug has cleared your system. Semaglutide has a half-life of roughly a week, so after eight weeks very little is pharmacologically active. That matters for two reasons. First, any weight you regained during that break reflects how semaglutide was working for you, which is clinically useful information. Second, and more practically, your tolerance resets to some degree, the dose your body was comfortable with in month three is not necessarily the dose it will tolerate on day one of restarting.

The side-effect profile of Wegovy is well established. Nausea, loose stools, reflux and fatigue cluster most heavily at the start of treatment and again at each dose step upward. After a break of this length, most prescribers treat a restart like a re-initiation: back to a lower dose, with a measured titration. That slower re-entry is the main reason people who struggled first time around often find the second attempt more manageable. What made you stop matters too, side effects that were purely gastrointestinal and temporary are very different from something like persistent severe stomach pain, which the MHRA's Drug Safety Update guidance on GLP-1 medicines identifies as a signal worth taking seriously before going back.

There is no guaranteed outcome either way. But two months is enough time to make an informed, unhurried decision rather than a reactive one, and that is the right framing.

The side effects that call for extra caution before you restart

Most people who stop Wegovy do so because of nausea or gut symptoms. Those are uncomfortable, but they are not a barrier to restarting with a lower dose and a slower titration. The timing of when side effects typically begin maps closely onto dose increases, which is why going back to an earlier dose usually brings relief.

A smaller group of side effects warrant a proper clinical conversation before you consider restarting at all. Acute pancreatitis is one: severe, persistent abdominal pain that radiates to the back, with or without vomiting, is the key symptom. The MHRA issued specific guidance on this in early 2026 because, while pancreatitis is an infrequent side effect, it can be serious and is a recognised risk with GLP-1 receptor agonists. If that was the reason you stopped, do not restart without speaking to a doctor. Similarly, a significant allergic reaction, persistent heart rate changes, or worsening of a pre-existing condition all need clinical input rather than a self-managed restart.

Gallbladder symptoms (right-sided or upper-centre abdominal pain, sometimes after eating) are also worth flagging before you go back on treatment. The NHS semaglutide medicines page lists these clearly alongside the more common side effects, and it is worth reading before any restart decision. For a broader picture of what people experience over time, how side effects can shift after six months is worth understanding too, including how diarrhea after six months on Wegovy tends to change in character and frequency compared with early treatment.

When to get medical help, and not to wait

This is a section worth reading even if you feel completely fine right now. If you do restart and develop any of the following, get help promptly rather than sitting it out. Severe stomach pain that reaches through to your back and does not settle within a few hours: seek urgent medical attention, as this can indicate pancreatitis. Signs of a serious allergic reaction (swelling of the face, throat or tongue, difficulty breathing) need an emergency response. Significant dehydration from repeated vomiting or diarrhoea, especially if you cannot keep fluids down, should prompt a call to 111 or your GP rather than waiting.

For most people, restarting means navigating a few days of nausea. But knowing the line between manageable adjustment and something that needs clinical input is exactly the kind of information a prescriber goes through with you before you restart. If you experience anything you are unsure about, you can also reach the nume aftercare team through the contact page, the team is available seven days a week. You can also report side effects directly to the MHRA via Yellow Card; this matters because semaglutide still carries a Black Triangle (▼) status, meaning regulators are actively collecting safety information.

If you stopped recently and are still experiencing effects from Wegovy, understanding what happens to side effects after stopping may answer some of what you're going through before you make any decision.

Making the restart decision: what a prescriber actually weighs up

Thinking about timing is sensible here. If you are restarting around a period when daily routine is disrupted (a busy run at work, a holiday coming up, the chaos of a school break) some people find it easier to begin on a Monday when the week is predictable. Not a rule; just a practical thought that some patients raise. Dose adjustments are easier to track when the rest of life is steady.

What a prescriber looks at: the original reason for stopping, whether the side effects have fully resolved, what dose you were on, any changes to your other medications or health since you stopped, and your weight trajectory. They will also look at the clinical picture as a whole rather than treating the restart as a simple administrative step. For context on the broader Wegovy treatment journey, the Wegovy overview covers the licence, the titration schedule, and what the evidence shows. Questions about the service or process are covered on the FAQs page.

The consultation at nume is free, includes a same-day clinical review by a GPhC-registered Independent Prescriber (a real clinician, not automated decision-making) and covers your full history. If you are ready to explore whether restarting is appropriate for you, check your eligibility and start your free consultation.